Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06058013 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

A Phase 3 study of Major Depressive Disorder, sponsored by Neumora Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
332
Enrollment target
20
Study locations

NCT06058013 is a Phase 3 study of Major Depressive Disorder that is actively recruiting participants, run by Neumora Therapeutics. The registered enrollment target is 332 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06058013, a Phase 3 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Neumora Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
332 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).

Conditions Studied

Major Depressive Disorder

Interventions

  • DRUG Placebo
  • DRUG NMRA-335140

Study Locations (20)

Florida

  • Neumora Investigator Site - Bradenton
  • Neumora Investigator Site - Hollywood
  • Neumora Investigator Site - Homestead
  • Neumora Investigator Site - Lauderhill
  • Neumora Investigator Site - Maitland
  • Neumora Investigator Sites - Miami
  • Neumora Investigator Site - Miami
  • Neumora Investigator Site - Miami
  • Neumora Investigator Site - Miami
  • Neumora Investigator Site - Miami
  • Neumora Investigator Site - Miami Lakes
  • Neumora Investigator Site - Miami Lakes
  • Neumora Investigator Site - Orlando

California

  • Neumora Investigator Site - Encino
  • Neumora Investigator Site - Garden Grove
  • Neumora Investigator Site - Los Alamitos
  • Neumora Investigator Site - Newport Beach
  • Neumora Investigator Site - Orange
  • Neumora Investigator Site - Santa Ana

Connecticut

  • Neumora Investigator Site - Norwalk

Trial Details

FieldValue
Enrollment Target 332 participants
Start Date 2023-12-20
Est. Completion 2026-06
Phase Phase 3

Sponsor

Neumora Therapeutics

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06058013

The ClinicalTrials.gov registry entry for NCT06058013 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (12% lower). The listed sponsor is Neumora Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06058013 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06058013 about?

NCT06058013 is a clinical study titled "Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder". This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatm...

What is the current status of trial NCT06058013?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2023-12-20. Estimated completion is 2026-06.

What conditions does trial NCT06058013 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT06058013?

The interventions under investigation include: Placebo (DRUG), NMRA-335140 (DRUG).

Who is sponsoring clinical trial NCT06058013?

This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06058013 being conducted?

This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.